Premium
Comparative studies on the expression of tumor‐associated glycoprotein (TAG‐72), CA 19‐9 and DU‐pan‐2 in normal, benign and malignant pancreatic tissue
Author(s) -
Takasaki Hideaki,
Tempero Margaret A.,
Uchida Eiji,
Büchler Markus,
Ness Marsha J.,
Burnett David A.,
Metzgar Richard S.,
Colcher David,
Schlom Jeffrey,
Pour Parviz M.
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910420508
Subject(s) - glycocalyx , pancreas , immunohistochemistry , pancreatic cancer , ductal cells , antigen , pancreatitis , monoclonal antibody , ca19 9 , pathology , immunocytochemistry , glycoprotein , pancreatic disease , biology , cancer , medicine , antibody , microbiology and biotechnology , endocrinology , immunology
Expression of tumor‐associated glycoprotein (TAG‐72) was examined by immunohistochemistry in pancreatic specimens from normal donors, and from patients with chronic pancreatitis and pancreatic cancer, and was compared with expression of CA 19‐9 and DU‐PAN‐2. In the normal pancreas, TAG‐72 was expressed in fewer ductal and ductular cells than were CA 19‐9 ( p < 0.05) and DU‐PAN‐2 ( P < 0.01 and 0.001 respectively), whereas in chronic pancreatitis all 3 antigens were expressed in ductal cells but only CA 19‐9 and DU‐PAN‐2 in ductular cells ( p <0.001). In the specimens from normal pancreas and chronic pancreatitis cases, TAG‐72 was localized in the Golgi region, whereas CA 19‐9 and DU‐PAN‐2 showed diffuse cytoplasmic and glycocalyx patterns. In pancreatic cancer, although the rate of expression of all 3 antigens was similar, their cellular localization differed significantly: only TAG‐72 was expressed in the Golgi region ( p < 0.001), whereas CA 19‐9 showed mainly glycocalyx ( p < 0.05) and/or intra‐luminal patterns ( p <0.01) compared with that of the other 2 antigens. We conclude that, due to differences in expression of TAG‐72 in benign versus malignant cells, the monoclonal antibody against TAG‐72 (B72.3) may be suitable for radioimmunodetection or radio‐immunotherapy of pancreatic cancer.